A new announcement from pharmaceutical company Roche has revealed the failure of a massive global Phase 3 trial testing its latest anti-amyloid Alzheimer's disease treatment. The failure marks another twist in the ongoing rollercoaster of research looking for drugs to reduce build-up of the protein…
